Skip to content Home / Companies / ATTO ATT
Attovia Therapeutics, Inc. (ATTO) XNAS BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Net insider buying (90d)
Latest ATTO Insider Trades
About Attovia Therapeutics, Inc. (ATTO) Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
Headquarters SAN CARLOS, CA
Listed 2026
Exchange XNAS https://www.attovia.com SEC filings for ATTO on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market purchase 25 4,422,201 $77.44M Open-market sale 92 423,228 $9.01M Grant or award 6 1,012,300
ATTO Insider Transactions (Form 4) 159 15 Form 4 filings on record, the earliest from Aug 6, 2026, newest first.
Date Insider Transaction Security Shares Price Value Aug 5, 2026 CW Colin Walsh - Director Open-market purchase Common Stock 85,000
Recent ATTO Form 8-K Filings 2
Recent ATTO Form 144 Notices of Proposed Sale 1 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 28, 2026 GOLDMAN SACHS GROUP INC Former 10% Owner 105,807 $2.22M View on EDGAR
ATTO Insider Trading - FAQ
What is the latest insider trade for ATTO? Attovia Therapeutics, Inc. (ATTO) had 15 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for ATTO runs to 15 Form 4 filings, the earliest from 2026-08-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying ATTO stock? 25 insider purchases of ATTO were filed in the last 90 days, totaling $77.44M.
How many insiders are selling ATTO stock? 92 insider sales of ATTO were filed in the last 90 days, totaling $9.01M.
Where can I see ATTO SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks ATTO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow ATTO insider buys? Create a free InsiderAlpha account and press Watch on this page to add ATTO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Aug 28, 2026 - Colin Walsh view on EDGAR Aug 28, 2026 - GOLDMAN SACHS GROUP INC view on EDGAR Aug 14, 2026 - Colin Walsh view on EDGAR Aug 14, 2026 - GOLDMAN SACHS GROUP INC view on EDGAR Aug 10, 2026 - Deep Track Biotechnology Master Fund, Ltd. view on EDGAR Aug 10, 2026 - venBio Global Strategic Fund IV, L.P. view on EDGAR Aug 8, 2026 - Redmile Group, LLC view on EDGAR Aug 7, 2026 - Sanofi view on EDGAR Aug 6, 2026 - Frazier Life Sciences XI, L.P. view on EDGAR
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track ATTO insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free CW
CW Colin Walsh - Director Open-market sale $29K
Aug 5, 2026
CW Colin Walsh - Director Open-market sale $34K
Aug 5, 2026
CW Colin Walsh - Director Open-market sale $75K
Aug 5, 2026
Market cap $1.02B
P/E ratio -
Dividend yield -
Average volume 405.3K
52 week high -
52 week low -
Today's high $24.39
Today's low $22.24
Open $22.24
Volume 292.6K
Previous close $22.25
Shares outstanding 45.65M
ATTO Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
90% Buying 10% Selling
25 insider purchases totaling $77.44M against 92 sales totaling $9.01M.
Most-Active ATTO Insiders - Last 90 Days 3 Other acquisition / disposition 36 219,111,776
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 988 $22.03 $22K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 447 $21.87 $10K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,332 $22.03 $29K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 200 $22.05 $4K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,556 $22.06 $34K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 3,402 $22.02 $75K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 200 $22.10 $4K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 480 $21.55 $10K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 100 $22.11 $2K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 753 $21.97 $17K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 672 $22.02 $15K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 6,970 $22.03 $154K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 400 $22.02 $9K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,180 $21.84 $26K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,040 $22.05 $23K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 300 $20.84 $6K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 443 $21.78 $10K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 200 $22.05 $4K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 700 $22.07 $15K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,163 $22.19 $26K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 100 $21.99 $2K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 6,763 $21.61 $146K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 76,418 $21.04 $1.61M
Aug 6, 2026 CW Colin Walsh - Director Other Common Stock 1,957,134 $0.00 -
Aug 6, 2026 CW Colin Walsh - Director Other Common Stock 478,498 $0.00 -
Aug 6, 2026 CW Colin Walsh - Director Open-market purchase Common Stock 500,000 $17.00 $8.50M
Aug 6, 2026 CW Colin Walsh - Director Other Series B Preferred Stock 18,181,830 $0.00 -
Aug 6, 2026 CW Colin Walsh - Director Other Series C Preferred Stock 4,445,275 $0.00 -
Aug 5, 2026 CW Colin Walsh - Director Open-market purchase Equity Swap 2,872 $21.22 $61K
Aug 5, 2026 CW Colin Walsh - Director Open-market purchase Equity Swap 28,717 $21.22 $609K
Aug 5, 2026 CW Colin Walsh - Director Open-market purchase Equity Swap 11,488 $21.22 $244K
Aug 5, 2026 CW Colin Walsh - Director Open-market purchase Equity Swap 45,588 $21.27 $970K
Aug 5, 2026 CW Colin Walsh - Director Open-market purchase Equity Swap 11,398 $21.27 $242K
Aug 5, 2026 CW Colin Walsh - Director Open-market purchase Equity Swap 5,744 $21.22 $122K
Aug 5, 2026 CW Colin Walsh - Director Open-market purchase Common Stock 85,000 $21.00 $1.78M
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 988 $22.03 $22K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 447 $21.87 $10K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,332 $22.03 $29K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 200 $22.05 $4K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,556 $22.06 $34K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 3,402 $22.02 $75K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 200 $22.10 $4K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 480 $21.55 $10K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 100 $22.11 $2K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 753 $21.97 $17K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 672 $22.02 $15K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 6,970 $22.03 $154K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 400 $22.02 $9K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,180 $21.84 $26K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,040 $22.05 $23K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 300 $20.84 $6K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 443 $21.78 $10K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 200 $22.05 $4K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 700 $22.07 $15K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 1,163 $22.19 $26K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 100 $21.99 $2K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 6,763 $21.61 $146K
Aug 5, 2026 CW Colin Walsh - Director Open-market sale Common Stock 76,418 $21.04 $1.61M
Aug 6, 2026 CW Colin Walsh - Director Other Common Stock 1,957,134 $0.00 -
Aug 6, 2026 CW Colin Walsh - Director Other Common Stock 478,498 $0.00 -
Aug 6, 2026 CW Colin Walsh - Director Open-market purchase Common Stock 500,000 $17.00 $8.50M
Aug 6, 2026 CW Colin Walsh - Director Other Series B Preferred Stock 18,181,830 $0.00 -
Aug 6, 2026 CW Colin Walsh - Director Other Series C Preferred Stock 4,445,275 $0.00 -
Aug 6, 2026 Redmile Group, LLC - 10% Owner Open-market purchase Common Stock 200,000 $17.00 $3.40M
Aug 6, 2026 Redmile Group, LLC - 10% Owner Open-market purchase Common Stock 400,000 $17.00 $6.80M
Aug 6, 2026 S Sanofi - 10% Owner Other Common Stock 782,855 - -
Aug 6, 2026 S Sanofi - 10% Owner Open-market purchase Common Stock 300,000 $17.00 $5.10M
Aug 6, 2026 S Sanofi - 10% Owner Other Series C Preferred Stock 782,855 - -
Aug 4, 2026 AY Angie You - Director Grant or award Stock Option (Right to Buy) 27,000 $0.00 -
Aug 4, 2026 MG Mitchell Gold - Director Grant or award Stock Option (Right to Buy) 27,000 $0.00 -
Aug 4, 2026 ZO Zaneta Odrowaz - Officer Grant or award Stock Option (Right to Buy) 140,000 $0.00 -
Aug 4, 2026 PV Petter Veiby - Officer Grant or award Stock Option (Right to Buy) 140,000 $0.00 -
Aug 4, 2026 HC Hubert Chen - Officer Grant or award Stock Option (Right to Buy) 140,000 $0.00 -
